Peer-reviewed article on Ortho RTi's Ortho-R Implants to aid in meniscus repair published in Regenerative Medicine and Therapeutics

KIRKLAND, QC, Dec. 20, 2017 /CNW Telbec/ - Ortho Regenerative Technologies Inc. (CSE: ORTH.CN) ("Ortho RTi" or the "Corporation"), an emerging Orthopaedic and Sports Medicine Technology company, today announced that a peer-reviewed article entitled "Freeze-Dried [Ortho-R] Injectable Surgical Implants for Meniscus Repair: Pilot Feasibility Studies in Ovine Models" has been published in the current issue of Regenerative Medicine and Therapeutics.

Clinical management of meniscus tears often involves partial meniscectomy, which can lead to osteoarthritis due to the tissue's limited healing response.  The purpose of the study reported in the article was to assess the feasibility of using Ortho RTi's "Ortho-R" hybrid implants to improve meniscus repair in ovine models.  An abstract of the article can be accessed on the internet at https://thescipages.org/Articles/regenerative-medicine/rmt-1-002.pdf.

Quoting from the article, "Complete repair and seamless repair tissue integration were observed in 1 out of 4 [Ortho-R] treated defects in the first study after 3 months and in 1 out of 2 [Ortho-R] treated defects in the second study after 6 weeks, while there was no healing with [platelet rich plasma] or wrapping alone. These pilot feasibility studies demonstrated that [Ortho-R] injectable implants display some potential to improve meniscus repair outcomes in pre-clinical models and could overcome some of the current limitations of meniscus repair by assisting in restoring meniscus structure and function."

The Corporation's Executive Chairman and CEO, Dr. Brent Norton, commented, "This is the second paper published this month that has shown the strong potential that our proprietary biopolymer platform holds for improving the success rate of soft tissue sports injury surgeries.  We are working diligently to advance the technology's development and look forward to updating all of our stakeholders as we progress."

Regenerative Medicine and Therapeutics is an open access peer-reviewed journal that publishes novel results and information in wide variety of techniques involved in replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function.  The journal accelerates the pace of research updates, discovery and innovation in various aspects of developmental biology, emerging technologies, regenerative biomedicine, tissue engineering.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.  Visit us on the internet at www.orthorti.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

SOURCE Ortho Regenerative Technologies Inc.

For further information: please contact: Stephen Kilmer, Investor & Media Relations, 647.872.4849, [email protected]